| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T3122 |
0-234 |
Sentence |
denotes |
Of 152 p on dual NA therapy since at least 12 months, the majority receive zidovudine-lamivudine (30.3%) followed by lamivudine-stavudine (27%), zidovudine-didanosine (21.7%), didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%). |
| T82871 |
0-234 |
Sentence |
denotes |
Of 152 p on dual NA therapy since at least 12 months, the majority receive zidovudine-lamivudine (30.3%) followed by lamivudine-stavudine (27%), zidovudine-didanosine (21.7%), didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%). |
